CD309 / VEGFR-2 / Flk-1 (esFlk1) Rabbit Polyclonal Antibody
CAT#: AP26035PU-N
CD309 / VEGFR-2 / Flk-1 (esFlk1) rabbit polyclonal antibody, Purified
Need it in bulk or conjugated?
Get a free quote
CNY 3,450.00
货期*
5周
规格
Cited in 1 publication. |
Specifications
Product Data | |
Applications | WB |
Recommend Dilution | Western blot: 1-5 µg/ml. |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Immunogen | Peptide of the C-terminal end of native Mouse soluble VEGFR-2/Flk-1 (GMEASLGDRIAMP). |
Specificity | This antibody detects endogenous sVEGFR-2/Flk-1. |
Formulation | PBS, pH 7.2 State: Purified State: Lyophilized purified IgG fraction |
Reconstitution Method | Centrifuge vial prior to opening. Restore in sterile water to a concentration of 0.1-1.0 mg/ml. |
Purification | Protein A Chromatography |
Conjugation | Unconjugated |
Storage Condition | Prior to reconstitution store at 2-8°C. |
Database Link | |
Background | Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant mouse esFlk-1 generated by alternative splicing consists of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP. |
Synonyms | VEGFR2, FLK1, KDR, VEGF Receptor 2 |
Reference Data |
Citations (1)
The use of this Antibodies has been cited in the following citations: |
---|
The effects of pioglitazone in cirrhotic rats with hepatopulmonary syndrome.
,null,
Journal of the Chinese Medical Association : JCMA
,PubMed ID 28969989
[Kdr]
|
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...